News

February 2016 Newsletter

With the start of a new year, we see new opportunities on the horizon with lung cancer treatments and we must work to maximize their impact and potential. With the approval of alectinib and osimertinib, we continue to see the rapid rise in the options available to our patients, and your IASLC continues its commitment to educate the oncology community and patients on these new developments.

DENVER – Non-small cell lung cancer (NSCLC) patients with common epidermal growth factor (EGFR) mutations and brain metastases showed improved progression-free survival (PFS) and response from the EGFR tyrosine kinase inhibitor (TKI) afatinib compared to standard platinum doublet chemotherapy.

DENVER – The International Association for the Study of Lung Cancer (IASLC) Foundation graciously accepted a gift of $25,600 to help find new and better lung cancer treatments in honor of the memory of a Denver-area lung cancer patient who recently passed away.

COLORADO SPRINGS – A Colorado-based Cleveland Browns fan club, the Pikes Peak Browns Backers, chose the International Association for the Study of Lung Cancer (IASLC) Foundation as one of the recipients of its annual charity donation in a show of support of club member Lisa Moran, a 44-year-old lung cancer survivor. The gift will help IASLC in its mission to find ways to conquer thoracic malignancies worldwide.

DENVER – An increase in the stage of non-small cell lung cancer (NSCLC) due to cancer positive lymph node (LN) discovery was more common following open chest surgery for lung lobe removal of early stage lung cancer compared to the closed chest procedure known as video assisted thoracic surgery (VATS).

DENVER – The requirement for tumor tissue specimens and associated analyses in order to participate in clinical trials appears to be a significant barrier to clinical trial enrollment and may delay treatment. Potential solutions to reducing or eliminating these barriers include routine tissue banking at diagnosis, easing use of available diagnostic samples, development of less invasive tests, faster turnaround time at central laboratories or allowing for local testing and more resources for timely tissue collection.

Pages